3′-CPR II CPG (Co-Polymer Coated)

High-Loading Chemical Phosphorylation Reagent CPR II CPG for Industrial-Scale Oligonucleotide Manufacturing

Product Overview

3′-CPR II CPG (Co-Polymer Coated) is a next-generation solid support specifically designed for efficient 3′-end phosphorylation in oligonucleotide synthesis.

Developed using Poresyn Solutions’ patented co-polymer coated CPG architecture, this advanced CPR II CPG combines the structural stability of controlled pore glass (CPG) with the high loading advantages of polymer-based supports, making it ideal for GMP-scale DNA and RNA oligonucleotide production.

This product is fully compatible with automated synthesizers and standard cleavage/deprotection protocols, enabling seamless integration into existing manufacturing platforms.

Loading Capacity

Our CPR II CPG （co-polymer） offers significantly enhanced loading compared to conventional functionalized CPG supports:

• 500Å: 160–220 μmol/g

• 1000Å: 80–100 μmol/g

• 2000Å: 40–50 μmol/g

Higher loading directly contributes to:

• Increased A260 output

• Higher full-length product (FLP) yield

• Reduced cost of goods (COG)

• Improved process scalability

Why Choose Poresyn Solutions’ CPR II CPG?

Optimized for 3′-End Phosphorylation

This 3′-CPR II CPG is engineered for reliable introduction of a 3′-phosphate group during solid-phase oligonucleotide synthesis.

Unlike traditional 3′-phosphate CPG materials, our co-polymer coated CPR II CPG demonstrates enhanced stability during:

• β-elimination (e.g., cyanoethyl deprotection)

• Standard cleavage procedures

• Harsh alkaline treatment conditions

This significantly reduces the risk of linker cleavage and yield loss.

Superior Structural Stability

Traditional modified CPG materials often suffer from pore collapse or particle fragmentation during synthesis and post-treatment.

Our CPR II CPG (co-polymer coated) maintains:

• Precise pore size integrity (500Å / 1000Å / 2000Å)

• No swelling during synthesis

• No silica shedding

• No pipeline clogging risks

• Stable backpressure under flow conditions

This ensures consistent performance in both R&D and GMP manufacturing environments.

Higher FLP Yield & Reduced Purification Costs

Thanks to its elevated loading and chemical inertness, our CPR II CPG enables:

• Significantly improved full-length product yield

• Crude purity improvements up to 30% higher vs. traditional CPG

• Reduced downstream purification burden

• Greater batch-to-batch consistency

For biotech and pharmaceutical manufacturers, this translates to:

• Lower purification costs

• Increased production efficiency

• Enhanced reproducibility in API-scale oligonucleotide synthesis

Applications

• 3′-phosphorylated DNA oligonucleotide synthesis

• 3′-phosphorylated RNA oligonucleotide synthesis

• ASO manufacturing

• siRNA production

• CRISPR gRNA synthesis

• GMP-scale oligonucleotide API production

Storage

Store at 2–8°C in a dry, sealed condition.

Customization & Technical Support

We offer flexible customization options for:

• Loading density adjustment

• Pore size optimization

• Special modification requirements

Our technical team is available to support process development and scale-up activities.

Samples & Documentation

• Certificate of Analysis (COA) available upon request

• Samples available for evaluation before large-scale production